Although lapatinib exhibited anti-tumor activity against BRD4-amplified tumor models, and gave significant combination activity with AZD5153, further investigation will be required to interrogate the role of NRG1 as a therapeutic target. This evidence concerns the gene BRD4 and neoplasm.